Catherine E. Richter

Catherine E. Richter

Auto-generated profile, based on publicly available information

Catherine E. Richter

Department of Pediatrics, University of Michigan Medical School, Ann Arbor, MI

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 July 2025 in Blood Advances
Verified
Journal Article
Open access
RARaghunath Azhwar
Raghunath Azhwar
CRCatherine E. Richter
Catherine E. Richter
MGMegan S. Griffin
Megan S. Griffin
SESylvia M. Emly
Sylvia M. Emly
MYMurat Yaman
Murat Yaman
JSJordan A. Shavit
Jordan A. Shavit
Deficiencies in coagulation factor VIII (FVIII, F8) result in the bleeding disorder hemophilia A. An emerging novel therapeutic strategy for bleeding disorders is to enhance hemostasis by limiting natural anticoagulants, such as antithrombin (AT3). To study pro/anticoagulant hemostatic balance in an in vivo model, we used genome editing to create null alleles for f8 and von Willebrand factor (vwf) in zebrafish, a model organism with a high degree of homology to the mammalian hemostatic system and unique attributes, including external development and optical transparency. f8 homozygous mutant larvae surprisingly formed normal thrombi when subjected to laser-mediated endothelial injury, had no overt signs of hemorrhage, although they did have a modest increase in mortality. We have previously shown that at3–/– larvae develop disseminated intravascular coagulation (DIC), with spontaneous thrombosis and fibrinogen consumption, resulting in a bleeding phenotype marked by secondary lack of induced thrombus formation upon endothelial injury. We found that with loss of FVIII (f8–/–;at3–/–), larvae no longer developed spontaneous fibrin thrombi and produced clots in response to endothelial injury. In contrast, homozygous loss of zebrafish Vwf failed to rescue the at3 DIC phenotype. These findings demonstrate an altered balance of natural anticoagulants that mitigates FVIII deficiency in zebrafish, similar to hemostatic drugs in the clinical development pipeline, and suggest that zebrafish FVIII might circulate independently of Vwf. Further exploration of this unique balance in zebrafish could provide novel insights into the treatment of hemophilia A and von Willebrand disease.

25 September 2025 in Blood Advances
Verified
Journal Article
Open access
BWBrooke N. Wolford
Brooke N. Wolford
QZQueena Yakun Zhao
Queena Yakun Zhao
KWKuan-Han H. Wu
Kuan-Han H. Wu
XYXinge Yu
Xinge Yu
CRCatherine E. Richter
Catherine E. Richter
ISIda Surakka
Ida Surakka
Venous thromboembolisms (VTEs) are a leading cause of morbidity and mortality. Although many genetic risk factors have been identified, a substantial portion of the heritability remains unexplained. In this study, we employed a genome-wide association study (GWAS) for VTE across 9 international cohorts of the Global Biobank Meta-Analysis Initiative to address this question, along with in vivo functional validation. In this multipopulation GWAS (VTE cases, 27 987; controls, 1 035 290), 38 genome-wide significant loci were identified, 4 of which were potentially novel. For each autosomal locus, we performed gene prioritization using 7 independent, yet converging, lines of evidence. Through prioritization, we identified genes associated with VTE through GWAS and/or functional studies (eg, F5, F11, VWF, STAB2, PLCG2, TC2N), functionally validated those that did not have evidence other than GWAS (TC2N, TSPAN15), and discovered 1 not previously associated with coagulation (RASIP1). We evaluated the function of 6 prioritized genes with strong genetic evidence, including F7 as a positive control, using laser-mediated endothelial injury to induce thrombosis in zebrafish after CRISPR/Cas9 knockdown. From this assay, we have supportive evidence for the role of RASIP1 and TC2N in the modification of human VTE and suggestive evidence for STAB2 and TSPAN15. This study expands on the currently identified genomic architecture of VTE through biobank-based, multipopulation GWASs, in silico candidate gene predictions, and in vivo functional follow-up of candidate genes.

31 March 2026 in Blood Advances
Verified
Journal Article
Open access
Guomin ShenGuomin Shen
Guomin Shen
DSDan Song
Dan Song
SLShixin Li
Shixin Li
XCXuejie Chen
Xuejie Chen
CRCatherine E. Richter
Catherine E. Richter
JTJian-Ke Tie
Jian-Ke Tie
Oral anticoagulants such as warfarin, which function as vitamin K antagonists (VKAs), have long been central to anticoagulation therapy. Warfarin inhibits vitamin K epoxide reductase (VKOR), thereby restricting the availability of reduced vitamin K and impairing γ-carboxylation and activation of vitamin K–dependent clotting factors (VKDCFs). However, warfarin’s clinical use is hindered by a narrow therapeutic index and marked interindividual variability, largely attributable to genetic variation in VKOR, yet it remains the only oral anticoagulant option for clinical conditions such as antiphospholipid antibody syndrome. γ-Glutamyl carboxylase (GGCX), the enzyme that directly modifies VKDCFs, represents an attractive but largely unexplored target for anticoagulation. Using a cell-based high-throughput screen of the Maybridge Hit-Finder compound library (comprising 14 400 drug-like molecules), we identified 21 compounds that inhibited γ-carboxylation of VKDCFs. Subsequent gene-deficient cell-based assays and in vitro enzymatic characterization revealed that compound HF13141-H5 selectively and potently inhibits GGCX activity, with nanomolar half-maximal inhibitory concentrations. Molecular docking with the recently resolved GGCX structure suggested that HF13141-H5 mimics the binding of reduced vitamin K, and site-directed mutagenesis confirmed the critical hydrogen bond with residue N290 within the substrate-binding pocket. Importantly, HF13141-H5 maintained full inhibitory potency against VKOR variants associated with warfarin resistance and demonstrated robust anticoagulant activity in a zebrafish laser-induced endothelial injury model. In summary, we describe the discovery and mechanistic characterization of HF13141-H5 as the first small-molecule GGCX inhibitor. By directly targeting GGCX, HF13141-H5 presents a promising strategy for developing next-generation anticoagulants that could overcome the limitations of warfarin, such as genetic variability and resistance.